In this issue
mAbs
Volume 4, Issue 3May/June 2012
View current issue
About the cover
The image portrays molecular models of human IgG1 and cell surface Fcγ receptors. The model of human IgG1 (green) is based on existing X-ray crystal...Continue reading
Most Popular Downloads
Bhavin S. Parekh, Elaine Berger, Sharon Sibley, et al.
Janice M. Reichert
Kai Zheng, Christopher Bantog and Robert Bayer
Upcoming Meetings
Antibody Design and Discovery
Jun 07-08, 2012
San Diego, CA
The 29th International Conference on the Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells
June 25-27, 2012
Mykonos, Greece
2nd Monoclonal Antibodies Summitt
Advances in Diagnostic & Therapeutic Antibody Development
March 12-13, 2013
London, UK
Call for speakers. Please email proposals to sabrina.daw@appelconsulting.co.uk
Editor-in-Chief
Janice M. Reichert, Ph.D.Medline/PubMed, PubMed Central, Science Citation Index Expanded, Biotechnology Citation Index, Biological Abstracts, Biosis Previews, Scopus
Important Journal Links
Submit your manuscript to mAbs
Recommend mAbs to your library
mAbs 101 - What are mAbs?
See this section for a comprehensive and up-to-date table with FDA-approved therapeutic mAbs.
Open Access in mAbs
The cost to make an original research paper OA is $750.00 USD.
For all other types of papers, the OA fee is $500.00 USD.
Special Discounted Subscription for Antibody Society Members
New feature! 'Like' mAbs on Facebook!
'Like' mAbs on Facebook to find out about newly added PDFs to forthcoming issues.
About the Journal
In January of 2009 we launched mAbs, an international peer-reviewed journal focused exclusively on antibodies.
Our mission is to provide a forum for communication on all topics relevant to antibody research and development, with a focus on therapeutics. In the last decade, there has been a rapid increase in antibody research and development performed by academia, government and industry located world wide. Novel antibody therapeutics are entering clinical study by commercial sponsors at an average rate of 50 per year that is predicted to continue well into the future. Over 30 mAb therapeutics have been approved and global sales of these products are approximately $40 billion. Our broad scope ensures that the journal's articles are of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community including readers concerned with technology transfer, legal issues, investment, regulatory requirements and strategic planning.
